Nanjing king-friend biochemical pharmaceutical announced that its subsidiary Jianjin Pharmaceutical has received a notice from the National Medical Products Administration regarding the approval and issuance of the registration certificate for Oxaliplatin Injection. The indications for this pharmaceutical include the treatment of metastatic colorectal cancer, adjuvant treatment for stage III colon cancer, and treatment for hepatocellular carcinoma.
健友股份：奥沙利铂注射液获国家药监局药品注册证书
Nanjing King-friend Biochemical Pharmaceutical: Oxaliplatin Injection has obtained the Drug Registration Certificate from the National Medical Products Administration.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated